Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of IFNα-Kinoid in adults with systemic lupus erythematosus
2015-001341-86Phase 2Terminated
- Sponsor
- Neovacs
- Start
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing IFNα-Kinoid with Placebo (2 arms). Primary endpoints: Neutralization of interferon gene signature and Clinical efficacy of IFNα-Kinoid. Started Sep 2015; status: terminated.
02
Drugs
IFN-K
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-001341-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001341-86.